TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36817782

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided treatment (PCT)
Number of subjects: 921

Group type: COMPARATOR
Intervention: Control group (standard antibiotic treatment)
Number of subjects: 921
Study: 36818155

Group type: EXPERIMENTAL
Intervention: Remotely prescribed and monitored long-term mHealth maintenance exercise programme
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 36818468

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) infusion using a 15-minute rate escalation protocol
Number of subjects: 123
Study: 36818595

Group type: EXPERIMENTAL
Intervention: 2 doses of mRNA vaccine
Number of subjects: 2486

Group type: EXPERIMENTAL
Intervention: 3 doses of mRNA vaccine
Number of subjects: 2486

Group type: COMPARATOR
Intervention: Black patients
Number of subjects: 2486

Group type: COMPARATOR
Intervention: Hispanic patients
Number of subjects: 2486
Study: 36818659

Group type: EXPERIMENTAL
Intervention: Cooperative learning intervention
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15
Study: 36818735

Group type: EXPERIMENTAL
Intervention: Sagittal balance restoration and assessment
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Different surgical technical options
Number of subjects: 176
Study: 36819512

Group type: EXPERIMENTAL
Intervention: Montelukast sodium OSF (oral soluble film)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Montelukast sodium CT (chewable tablet)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Montelukast sodium OSF without water
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Montelukast sodium OSF with water
Number of subjects: 60

Group type: COMPARATOR
Intervention: Montelukast sodium CT with water
Number of subjects: 60
Study: 36819685

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement + placebo (SU-PL)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement + probiotics (SU-PR)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (individualized diet)
Number of subjects: 31
Study: 36819683

Group type: EXPERIMENTAL
Intervention: Roasted barley flakes
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Roasted oat flakes
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Traditional barley flakes
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Traditional oat flakes
Number of subjects: 32

Group type: COMPARATOR
Intervention: White toast bread (control)
Number of subjects: 32
Study: 36820098

Group type: EXPERIMENTAL
Intervention: BGB-DXP593 5 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BGB-DXP593 15 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BGB-DXP593 30 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36820100

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (systolic target 130-140 mm Hg within 1 h; maintained for 72 h)
Number of subjects: 2196

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure management (systolic target <180 mm Hg)
Number of subjects: 2196
Study: 36820878

Group type: EXPERIMENTAL
Intervention: Helmet noninvasive ventilation
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual respiratory support
Number of subjects: 320
Study: 36820931

Group type: EXPERIMENTAL
Intervention: Norfloxacin prophylaxis
Number of subjects: 472

Group type: COMPARATOR
Intervention: No norfloxacin prophylaxis (Control)
Number of subjects: 472
Study: 36820984

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study: 36820983

Group type: EXPERIMENTAL
Intervention: IV golimumab
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: IV golimumab and Infliximab
Number of subjects: 1270
Study: 36821132

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy plus lapatinib
Number of subjects: 630

Group type: COMPARATOR
Intervention: Adjuvant chemoradiotherapy plus placebo
Number of subjects: 630
Study: 36821333

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Behavior therapy (BT)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 3
Study: 36821334

Group type: EXPERIMENTAL
Intervention: Four-session version of the eating disorder prevention program
Number of subjects: 63

Group type: COMPARATOR
Intervention: Two-session version of the eating disorder prevention program
Number of subjects: 63
Study: 36821344

Group type: EXPERIMENTAL
Intervention: PTSD Coach app
Number of subjects: 0
Study: 36821354

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg every 2 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 18
Study: 36821366

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: SMS and phone calls
Number of subjects: 264

Group type: COMPARATOR
Intervention: Routine standard care
Number of subjects: 264
Study: 36821406

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 64
Study: 36821575

Group type: EXPERIMENTAL
Intervention: Keystone flap for wide excision defects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digit-sparing alternative for subungual melanoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy with predictive nomograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy with immediate lymphatic reconstruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimally invasive modalities for in-transit melanoma management
Number of subjects: 0
Study: 36821597

Group type: EXPERIMENTAL
Intervention: Postpartum patient navigation program
Number of subjects: 50
Study: 36821613

Group type: EXPERIMENTAL
Intervention: Thrombospondin Type-1 Domain 7A Autoantibodies
Number of subjects: 0
Study: 36821617

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36821767

Group type: EXPERIMENTAL
Intervention: AUTO3 (CD19/22 dual-targeting CAR-T) plus pembrolizumab
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: AUTO3 (CD19/22 dual-targeting CAR-T)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Outpatient administration of AUTO3
Number of subjects: 52
Study: 36821768

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel) autologous anti-CD19 CAR T-cell therapy (2 × 10^6 cells per kg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel) autologous anti-CD19 CAR T-cell therapy
Number of subjects: 101
Study: 36821775

Group type: EXPERIMENTAL
Intervention: REL-1017
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 36821787

Group type: EXPERIMENTAL
Intervention: Fluid Overload (FO) ≥ 5% at Day 1
Number of subjects: 5079

Group type: EXPERIMENTAL
Intervention: Fluid Overload (FO) ≥ 10% at Day 1
Number of subjects: 5079

Group type: EXPERIMENTAL
Intervention: Fluid Overload (FO) peak at Day 2
Number of subjects: 5079

Group type: EXPERIMENTAL
Intervention: Fluid Overload (FO) ≥ 5% at Day 2
Number of subjects: 5079

Group type: EXPERIMENTAL
Intervention: Fluid Overload (FO) ≥ 10% at Day 2
Number of subjects: 5079
Study: 36821818

Group type: EXPERIMENTAL
Intervention: Remote patient monitoring with ePROs and biometrics (blood pressure, oxygen saturation, pulse, weight, temperature)
Number of subjects: 36
Study: 36821833

Group type: EXPERIMENTAL
Intervention: Digital integrated health care platform (group B)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Digital integrated health care platform with feedback (group C)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Routine diabetes care (group A)
Number of subjects: 294
Study: 36821841

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 9723

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 9723
Study: 36821847

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 195

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 195
Study: 36821851

Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 241
Study: 36822031

Group type: EXPERIMENTAL
Intervention: Telephone delivered problem-solving treatment
Number of subjects: 99

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 99
Study: 36822079

Group type: EXPERIMENTAL
Intervention: Pecan-enriched diet (68 g of pecans/d)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (nut-free diet)
Number of subjects: 44
Study: 36822130

Group type: EXPERIMENTAL
Intervention: Capmatinib
Number of subjects: 92
Study: 36822161

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus camrelizumab therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy
Number of subjects: 34
Study: 36822187

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Moderate-Intensity Aerobic Training (MAT)
Number of subjects: 55
Study: 36822238

Group type: EXPERIMENTAL
Intervention: Smartphone application for anthropometric body measurements
Number of subjects: 322
Study: 36822255

Group type: EXPERIMENTAL
Intervention: Intravenous Shenfu injection (80mL Shenfu injection + 70mL 5% glucose injection)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo group (150mL 5% glucose injection)
Number of subjects: 326
Study: 36822256

Group type: EXPERIMENTAL
Intervention: Bard Covera Plus covered stent mated with multibranched endovascular repair or iliac branch devices
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Adjunctive relining stents
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Patient-specific devices
Number of subjects: 284
Study: 36822279

Group type: EXPERIMENTAL
Intervention: Presence of single fibroids
Number of subjects: 2578

Group type: EXPERIMENTAL
Intervention: Presence of multiple fibroids
Number of subjects: 2578

Group type: EXPERIMENTAL
Intervention: Presence of small fibroid volume
Number of subjects: 2578

Group type: EXPERIMENTAL
Intervention: Presence of fibroids (any type)
Number of subjects: 2578

Group type: COMPARATOR
Intervention: Pregnancies without fibroids
Number of subjects: 2578
Study: 36822371

Group type: EXPERIMENTAL
Intervention: Vibrating capsule, once daily, 5 days a week for 8 weeks
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo, once daily, 5 days a week for 8 weeks
Number of subjects: 312
Study: 36822394

Group type: EXPERIMENTAL
Intervention: High-protein, mycoprotein-rich, non-animal-derived diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Omnivorous diet
Number of subjects: 16
Study: 36822634

Group type: EXPERIMENTAL
Intervention: Ecleralimab (4 mg once-daily inhaled)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 36822667

Group type: EXPERIMENTAL
Intervention: Durvalumab (durva) with radiation therapy (RT) for 7 weeks followed by adjuvant durvalumab for 1 year
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Durvalumab (durva) with radiation therapy (RT) for 7 weeks
Number of subjects: 26
Study: 36822669

Group type: EXPERIMENTAL
Intervention: I/T/DIN/GM-CSF
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: I/T/TEMS
Number of subjects: 17
Study: 36822801

Group type: EXPERIMENTAL
Intervention: Happy Mother Healthy Baby psychosocial intervention delivered by non-specialist providers
Number of subjects: 35
Study: 36822808

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in homeless population during first testing session
Number of subjects: 1249

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in homeless population during second testing session
Number of subjects: 1249

Group type: COMPARATOR
Intervention: SARS-CoV-2 seroprevalence in general population during first testing session
Number of subjects: 1249

Group type: COMPARATOR
Intervention: SARS-CoV-2 seroprevalence in general population during second testing session
Number of subjects: 1249

Group type: EXPERIMENTAL
Intervention: Increased risk factors for COVID-19 infection
Number of subjects: 1249

Group type: EXPERIMENTAL
Intervention: Decreased risk factors for COVID-19 infection
Number of subjects: 1249
Study: 36822818

Group type: COMPARATOR
Intervention: Cardiac MR (CMR) assessment at 6 months and 12 months post-infection
Number of subjects: 534

Group type: COMPARATOR
Intervention: Cardiac MR (CMR) assessment
Number of subjects: 534

Group type: COMPARATOR
Intervention: Comparison with 92 healthy controls
Number of subjects: 534
Study: 36822817

Group type: EXPERIMENTAL
Intervention: Healthcare worker status
Number of subjects: 168
Study: 36822839

Group type: EXPERIMENTAL
Intervention: GSK3640254 (GSK'254) 200 mg once daily from Days 11 to 20 and a single dose of cocktail + GSK'254 200 mg on Day 21
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GSK3640254 (GSK'254) 200 mg once daily
Number of subjects: 20
Study: 36822922

Group type: EXPERIMENTAL
Intervention: Liver transplantation (LT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triplet chemotherapy + antiEGFR (Control)
Number of subjects: 0
Study: 36823106

Group type: EXPERIMENTAL
Intervention: AZD4017
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 36823150

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day orally; neoadjuvant phase for 42 days and adjuvant phase to 12 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GC group; gemcitabine 1250 mg/m2, dosage not fully specified)
Number of subjects: 0
Study: 36823164

Group type: EXPERIMENTAL
Intervention: Home non-invasive mechanical ventilation (HMV) with home oxygen therapy (HOT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home oxygen therapy (HOT) alone
Number of subjects: 0
Study: 36823200

Group type: EXPERIMENTAL
Intervention: gB/MF59 vaccine candidate
Number of subjects: 0
Study: 36823302

Group type: EXPERIMENTAL
Intervention: Vorasidenib 50 mg once daily (q.d.)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg once daily (q.d.)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 49
Study: 36823349

Group type: EXPERIMENTAL
Intervention: Dostarlimab 500 mg every 3 weeks for four cycles, then 1000 mg every 6 weeks
Number of subjects: 377
Study: 36823396

Group type: EXPERIMENTAL
Intervention: 2022 ELN favorable group
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: 2022 ELN adverse group
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: 2022 genetic-risk groups
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Intermediate and adverse groups in patients aged ≥60 years
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Intermediate-risk and adverse-risk patients in younger African-American patients
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Favorable and intermediate groups in younger African-American patients
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Favorable and intermediate groups in Hispanic patients
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: 2022 and 2017 ELN classifications
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: Favorable-risk patients with myelodysplasia-related mutations
Number of subjects: 1637
Study: 36823526

Group type: EXPERIMENTAL
Intervention: PriCARE/CARIÑO intervention with usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study: 36823559

Group type: EXPERIMENTAL
Intervention: Dialogue-based webinar intervention facilitated by a LTCW and a medical expert, guided by an evidence-based COVID-19 vaccine decision tool.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Curated social media web application intervention featuring interactive, dynamic content about COVID-19 and relevant vaccines.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual practice directing participants to online public health information about COVID-19 vaccines.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All interventions (webinar, social media app, enhanced usual practice)
Number of subjects: 0
Study: 36823567

Group type: EXPERIMENTAL
Intervention: PE plus MCE
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MCE
Number of subjects: 120

Group type: COMPARATOR
Intervention: PE alone
Number of subjects: 120
Study: 36823645

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telehealth delivery of treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational interviewing communication techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assistance with scheduling of assigned treatments
Number of subjects: 0
Study: 36823955

Group type: EXPERIMENTAL
Intervention: Implantable Shock Absorber (ISA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High Tibial Osteotomy (HTO)
Number of subjects: 0
Study: 36824039

Group type: EXPERIMENTAL
Intervention: Stepping exergame training for 12 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional exercise (active control group) for 12 weeks
Number of subjects: 18
Study: 36824050

Group type: EXPERIMENTAL
Intervention: Mobile Health and Financial Incentives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36824052

Group type: EXPERIMENTAL
Intervention: Betamethasone 17-valerate 0.1% (n = 18)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% (n = 18)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Betamethasone 17-valerate 0.1%
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1%
Number of subjects: 36
Study: 36824387

Group type: EXPERIMENTAL
Intervention: Multispectral optoacoustic tomography (MSOT) at 800 nm
Number of subjects: 10
Study: 36824456

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived cells (BMC), 100 million cells injected during CABG surgery
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 143
Study: 36824611

Group type: EXPERIMENTAL
Intervention: SPSPII score system applied before treatment
Number of subjects: 231

Group type: COMPARATOR
Intervention: SPSP score
Number of subjects: 231

Group type: COMPARATOR
Intervention: Disease severity scores (DSS)
Number of subjects: 231
Study: 36824650

Group type: EXPERIMENTAL
Intervention: Liver Transplantation (LT)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Renal Transplantation (RT)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Glucocorticoids use
Number of subjects: 215

Group type: COMPARATOR
Intervention: Acute events (graft rejection and infection)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Prospective follow-up (pDIABGRAFT)
Number of subjects: 215
Study: 36824785

Group type: EXPERIMENTAL
Intervention: Spring Forest Qigong™ practice
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: P.Volve low-intensity exercises
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy control group (n=28)
Number of subjects: 32
Study: 36824823

Group type: EXPERIMENTAL
Intervention: Active transspinal stimulation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham transspinal stimulation
Number of subjects: 45
Study: 36824884

Group type: EXPERIMENTAL
Intervention: Smartphone intervention for medication assisted treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study: 36824929

Group type: EXPERIMENTAL
Intervention: Spring Forest Qigong™ intervention practiced at least 3 times per week for 12 weeks, using an online video combining movement with kinesthetic imagery.
Number of subjects: 23
Study: 36825238

Group type: EXPERIMENTAL
Intervention: Tongue image-based diagnostic model
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Tongue coating microbiome-based model using genus data
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Tongue coating microbiome-based model using species data
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Three tongue image-based models
Number of subjects: 937

Group type: COMPARATOR
Intervention: Combination of eight blood biomarkers
Number of subjects: 937
Study: 36825252

Group type: EXPERIMENTAL
Intervention: WHO case definition
Number of subjects: 263218

Group type: EXPERIMENTAL
Intervention: UKHSA case definition
Number of subjects: 263218

Group type: EXPERIMENTAL
Intervention: ECDC case definition
Number of subjects: 263218

Group type: EXPERIMENTAL
Intervention: CDC case definition
Number of subjects: 263218

Group type: COMPARATOR
Intervention: Patients who did not meet case definitions
Number of subjects: 263218
Study: 36825610

Group type: EXPERIMENTAL
Intervention: Perception threshold tracking
Number of subjects: 80

Group type: COMPARATOR
Intervention: Corneal confocal microscopy
Number of subjects: 80
Study: 36825693

Group type: EXPERIMENTAL
Intervention: PF-05212377 (SAM760)
Number of subjects: 0
Study: 36825887

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (non-exposed infants)
Number of subjects: 49
Study: 36825895

Group type: EXPERIMENTAL
Intervention: Prediction model based on baseline quality of life, admission type, and Glasgow Coma Scale
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: External validation of the prediction model
Number of subjects: 1804
Study: 36825929

Group type: COMPARATOR
Intervention: No trauma
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Accidental trauma
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Interpersonal trauma
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: PTSD
Number of subjects: 914
Study: 36826074

Group type: EXPERIMENTAL
Intervention: Module 1: online supervised group-based (M1)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Module 2: online unsupervised (M2)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Module 3: in-person supervised (M3)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Online exercise programs (M1, M2)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Module 3 (M3)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Personalized exercise programs
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Online exercise programs
Number of subjects: 92
Study: 36826464

Group type: EXPERIMENTAL
Intervention: FT-6876, a CBP/p300 bromodomain inhibitor
Number of subjects: 0